This compound is a small molecule inhibitor primarily utilized in medicinal chemistry for the development of therapeutic agents, particularly in the treatment of hormone-refractory prostate cancer. It specifically targets the CYP17A1 enzyme, which is involved in androgen synthesis, thereby reducing androgen levels and slowing the growth of prostate cancer cells. Its unique chemical features, including the trifluoromethyl and sulfonyl groups, enhance its potency, selectivity, and pharmacokinetic properties in drug discovery programs. Researchers may also investigate its potential in treating other hormone-dependent cancers, as well as its use in biochemical assays to study protein-ligand interactions or as a lead compound for structural refinement.